Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative)							1 Months Ended		9 Months Ended	12 Months Ended	36 Months Ended
Commitments and Contingencies (Details Narrative)	Sep. 26, 2019 USD ($)	Sep. 13, 2018 USD ($)	Sep. 13, 2018 EUR (€)	Aug. 12, 2016 USD ($)	May 05, 2016 USD ($)	May 05, 2016 AUD ($)	May 30, 2017 USD ($)	Jun. 30, 2012	Mar. 31, 2020 USD ($) shares	Jun. 30, 2018 USD ($)	Mar. 31, 2015 USD ($)	Jul. 02, 2019 USD ($)	Jun. 30, 2019 USD ($)
Convertible note									$ 169,500
Penalty amount											$ 30,000
Right-of-use assets									24,959
Total lease liabilities									27,335
Royalties percentage		2.00%	2.00%
Accounting Standards Update 2016-02 [Member]
Right-of-use assets												$ 46,696
Total lease liabilities												$ 46,696
Incremental borrowing rate												6.00%
Royalty Agreement Terms [Member]
Operating leases income statement revenue percentage								2.00%
License Agreement Terms [Member]
Operating leases income statement revenue percentage								5.00%
New Five-Year Operating Lease Agreement [Member]
Operating lease term					5 years	5 years
Payments for rent					$ 2,469
New Five-Year Operating Lease Agreement [Member] \| AUD Currency [Member]
Payments for rent						$ 3,606
Manufacturing Services Agreement [Member] \| Minimum [Member]
Anticipated milestone payment				$ 2,500,000
Manufacturing Services Agreement [Member] \| Maximum [Member]
Anticipated milestone payment				$ 5,000,000
Amatsigroup Agreement [Member]
Payments description				The Company anticipates that its payments to Amatsigroup under the MSA will range between $2.5 million and $5.0 million over three years, when the finished drug product is manufactured and released for clinical trials. The Company has spent a total of $1,689,146 of costs to date under this contract of which $1,689,146 was expensed in prior years. The MSA shall continue for a term of three years unless extended by mutual agreement in writing with a possible extension currently under consideration.
Contract cost									1,689,146	$ 1,689,146
One-Year Collaboration Agreement [Member]
Payment for services		$ 59,508
One-Year Collaboration Agreement [Member] \| Euros [Member]
Payment for services \| €			€ 52,000
Two-Year Collaboration Agreement [Member]
Payment for services		$ 45,775
Two-Year Collaboration Agreement [Member] \| Euros [Member]
Payment for services \| €			€ 40,000
From 2012 through the 2014 [Member]
Penalty amount									10,000
Regal Consulting, LLC [Member]
Loss contingency amount									$ 400,000
Number of shares issued for services \| shares									60,000
Regal Consulting, LLC [Member] \| 2017 Note [Member]
Convertible note							$ 106,500
Penalty amount							$ 98,000
Foley Shechter [Member]
Legal fees	$ 151,032
Potential liability reduction	$ 51,032